Where EGF receptors transmit their signals

Nancy Lill, Nurettin Ilter Sever

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Excessive signaling by receptor tyrosine kinases (RTKs) can cause cancer. What molecular mechanisms normally control RTK signaling? Are they defective in tumors? If so, should therapeutics be developed to restore particular regulatory pathways to cancer cells? These questions have been approached through mechanistic studies of a prototypical RTK, the epidermal growth factor receptor (EGFR). EGFR signaling is mediated and regulated by both signaling and trafficking effectors. The amplitude of receptor-proximal signals changes as EGFRs move along the degradative trafficking pathway from the cell surface, to endosomes, and into lysosomes. To optimize therapeutic suppression of receptor oncogenicity, it may be crucial to target EGFRs that are signaling from a specific site in the trafficking pathway. Research suggests that EGFRs at the plasma membrane produce the bulk of the global transcriptional response to EGF. EGFRs localized between the internalization and early endosome fusion stages of the pathway enrich the expression of transcripts associated with cancer. EGFRs at later trafficking checkpoints controlled by the endosomal sorting complex required for transport (ESCRT) complexes II and III do not contribute substantially to the EGFR-mediated transcriptional response. These results suggest that therapeutics targeting the receptors at the earliest stages of degradative trafficking might be most effective.

Original languageEnglish (US)
Article numberpe41
JournalScience signaling
Volume5
Issue number243
DOIs
StatePublished - Sep 25 2012

Fingerprint

Endosomal Sorting Complexes Required for Transport
Epidermal Growth Factor Receptor
Endosomes
Receptor Protein-Tyrosine Kinases
Neoplasms
Lysosomes
Epidermal Growth Factor
Cell membranes
Therapeutics
Cell Membrane
Tumors
Fusion reactions
Cells
ErbB Receptors
Research

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Lill, Nancy ; Sever, Nurettin Ilter. / Where EGF receptors transmit their signals. In: Science signaling. 2012 ; Vol. 5, No. 243.
@article{bc21f51c197149ea9e7ad29864c00675,
title = "Where EGF receptors transmit their signals",
abstract = "Excessive signaling by receptor tyrosine kinases (RTKs) can cause cancer. What molecular mechanisms normally control RTK signaling? Are they defective in tumors? If so, should therapeutics be developed to restore particular regulatory pathways to cancer cells? These questions have been approached through mechanistic studies of a prototypical RTK, the epidermal growth factor receptor (EGFR). EGFR signaling is mediated and regulated by both signaling and trafficking effectors. The amplitude of receptor-proximal signals changes as EGFRs move along the degradative trafficking pathway from the cell surface, to endosomes, and into lysosomes. To optimize therapeutic suppression of receptor oncogenicity, it may be crucial to target EGFRs that are signaling from a specific site in the trafficking pathway. Research suggests that EGFRs at the plasma membrane produce the bulk of the global transcriptional response to EGF. EGFRs localized between the internalization and early endosome fusion stages of the pathway enrich the expression of transcripts associated with cancer. EGFRs at later trafficking checkpoints controlled by the endosomal sorting complex required for transport (ESCRT) complexes II and III do not contribute substantially to the EGFR-mediated transcriptional response. These results suggest that therapeutics targeting the receptors at the earliest stages of degradative trafficking might be most effective.",
author = "Nancy Lill and Sever, {Nurettin Ilter}",
year = "2012",
month = "9",
day = "25",
doi = "10.1126/scisignal.2003341",
language = "English (US)",
volume = "5",
journal = "Science Signaling",
issn = "1937-9145",
publisher = "American Association for the Advancement of Science",
number = "243",

}

Where EGF receptors transmit their signals. / Lill, Nancy; Sever, Nurettin Ilter.

In: Science signaling, Vol. 5, No. 243, pe41, 25.09.2012.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Where EGF receptors transmit their signals

AU - Lill, Nancy

AU - Sever, Nurettin Ilter

PY - 2012/9/25

Y1 - 2012/9/25

N2 - Excessive signaling by receptor tyrosine kinases (RTKs) can cause cancer. What molecular mechanisms normally control RTK signaling? Are they defective in tumors? If so, should therapeutics be developed to restore particular regulatory pathways to cancer cells? These questions have been approached through mechanistic studies of a prototypical RTK, the epidermal growth factor receptor (EGFR). EGFR signaling is mediated and regulated by both signaling and trafficking effectors. The amplitude of receptor-proximal signals changes as EGFRs move along the degradative trafficking pathway from the cell surface, to endosomes, and into lysosomes. To optimize therapeutic suppression of receptor oncogenicity, it may be crucial to target EGFRs that are signaling from a specific site in the trafficking pathway. Research suggests that EGFRs at the plasma membrane produce the bulk of the global transcriptional response to EGF. EGFRs localized between the internalization and early endosome fusion stages of the pathway enrich the expression of transcripts associated with cancer. EGFRs at later trafficking checkpoints controlled by the endosomal sorting complex required for transport (ESCRT) complexes II and III do not contribute substantially to the EGFR-mediated transcriptional response. These results suggest that therapeutics targeting the receptors at the earliest stages of degradative trafficking might be most effective.

AB - Excessive signaling by receptor tyrosine kinases (RTKs) can cause cancer. What molecular mechanisms normally control RTK signaling? Are they defective in tumors? If so, should therapeutics be developed to restore particular regulatory pathways to cancer cells? These questions have been approached through mechanistic studies of a prototypical RTK, the epidermal growth factor receptor (EGFR). EGFR signaling is mediated and regulated by both signaling and trafficking effectors. The amplitude of receptor-proximal signals changes as EGFRs move along the degradative trafficking pathway from the cell surface, to endosomes, and into lysosomes. To optimize therapeutic suppression of receptor oncogenicity, it may be crucial to target EGFRs that are signaling from a specific site in the trafficking pathway. Research suggests that EGFRs at the plasma membrane produce the bulk of the global transcriptional response to EGF. EGFRs localized between the internalization and early endosome fusion stages of the pathway enrich the expression of transcripts associated with cancer. EGFRs at later trafficking checkpoints controlled by the endosomal sorting complex required for transport (ESCRT) complexes II and III do not contribute substantially to the EGFR-mediated transcriptional response. These results suggest that therapeutics targeting the receptors at the earliest stages of degradative trafficking might be most effective.

UR - http://www.scopus.com/inward/record.url?scp=84866861514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866861514&partnerID=8YFLogxK

U2 - 10.1126/scisignal.2003341

DO - 10.1126/scisignal.2003341

M3 - Review article

C2 - 23012653

AN - SCOPUS:84866861514

VL - 5

JO - Science Signaling

JF - Science Signaling

SN - 1937-9145

IS - 243

M1 - pe41

ER -